{
  "id": 735389,
  "title": "AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants",
  "url": "https://urgent.news/2026/08/13/abcellera-announces-pricing-of-oversubscribed-200-million-public",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T04:14:07.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-common-shares-and-pre-funded-warrants"
  },
  "original_language": "en",
  "account": null,
  "summary": "VANCOUVER, British Columbia — AbCellera Biologics Inc. (Nasdaq: ABCL) (“AbCellera”) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}